With the ending of the FES-funding, the financing of the public-private partnerships via Technological Top Institutes (TTI's) ended. For the transition phase, the Ministry of Economic Affairs reserved a budget of over nine million euros that is distributed by the LSH-TKI. From this transition budget, five million euro’s of subsidies are made available for promising projects from the existing portfolio of the Center of Translational Molecular Medicine (CTMM) and BioMedical Materials (BMM).
The following eleven propositions, the so called ' research pearls' have been selected:
1. Prostate Cancer Molecular Medicine (PCMM) is searching for new biomarkers (risk indicators) for prostate cancer and developing imaging techniques to screen the effectiveness of treatments.
2. Breast CARE is developing tests and searching for biomarkers that enable better prediction in advance of what combination of drugs has the best chance to kill all cancer cells.
3. The PREDICCt consortium combines the latest insights into the causes of diabetes mellitus type 2 with innovative techniques to find new biomarkers for the disease and related complications.
4. INCOAG develops new tests for easily and accurately assessing the risk of thrombosis in patients.
5. COHFAR pursues the great need for the early identification of patients at risk of heart failure or cardiac arrhythmias, as well as improvement of the response to cardiac pacemakers and ICDs.
6. MARS is developing tests that give quick and accurate information about individual patients with sepsis (blood poisoning), which is increasingly common and a major cause of death in hospitals.
7. Within VOLTA new technologies are being developed to treat cancer by using sound waves (high intensity focused ultrasound) and thereby locally heating tumors, enabling treatment of patients without surgery.
8. BONE IP aims at the development of bone implants with improved biological capacity and thereby enables fast healing of large bone defects and early and durable fixation of bone implants.
9. iValve aims at the development of living, native valves or blood vessels from the patient’s own cell by tissue engineering.
10. SMARTCARE II aims at structurally strengthening the heart, contributing more effectively to the function of the heart muscle and the fight against heart failure.
11. TRAMMPOLIN focuses on the design of a new artificial meniscus made from very strong, flexible and durable synthetics.